Patents by Inventor Ari Andrew Gershon

Ari Andrew Gershon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release olanzapine formulations
    Patent number: 11813359
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 14, 2023
    Assignee: Teva Pharmaceuticals International GMBH
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Sustained Release Olanzapine Formulations
    Publication number: 20210046007
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: May 11, 2020
    Publication date: February 18, 2021
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Sustained release olanzapine formulations
    Patent number: 10646443
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 12, 2020
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Sustained Release Olanzapine Formulations
    Publication number: 20180263911
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 20, 2018
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon